Edition:
India

Aeterna Zentaris Inc (AEZS.OQ)

AEZS.OQ on NASDAQ Stock Exchange Capital Market

4.20USD
20 Mar 2019
Change (% chg)

$-0.02 (-0.47%)
Prev Close
$4.22
Open
$4.22
Day's High
$4.24
Day's Low
$4.17
Volume
10,179
Avg. Vol
69,073
52-wk High
$4.36
52-wk Low
$1.12

Latest Key Developments (Source: Significant Developments)

Aeterna Zentaris Announces Strategic Review And Engagement Of Financial Advisor
Wednesday, 13 Mar 2019 

March 12 (Reuters) - Aeterna Zentaris Inc ::AETERNA ZENTARIS ANNOUNCES STRATEGIC REVIEW AND ENGAGEMENT OF FINANCIAL ADVISOR.AETERNA ZENTARIS INC - SPECIAL COMMITTEE HAS APPROVED ENGAGEMENT BY COMPANY OF TORREYA AS ITS FINANCIAL ADVISOR.AETERNA ZENTARIS - TORREYA IS WORKING WITH MANAGEMENT TO ASSIST SPECIAL COMMITTEE AND BOARD OF DIRECTORS IN CONSIDERING A WIDE RANGE OF TRANSACTIONS.AETERNA ZENTARIS INC - CONSIDERING POTENTIAL SALE OF COMPANY.AETERNA ZENTARIS - CONSIDERING OPPORTUNITIES FOR LICENSE OF MACIMORELIN OUTSIDE OF U.S. AND CANADA, OTHER MONETIZATION DEALS RELATING TO MACIMORELIN.  Full Article

Aeterna Zentaris Receives Positive CHMP Opinion On Macimorelin For Diagnosis Of Adult Growth Hormone Deficiency
Monday, 19 Nov 2018 

Nov 19 (Reuters) - Aeterna Zentaris Inc ::AETERNA ZENTARIS (AEZS) RECEIVES POSITIVE CHMP OPINION OF MACIMORELIN FOR DIAGNOSIS OF ADULT GROWTH HORMONE DEFICIENCY.AETERNA ZENTARIS INC - RECOMMENDATION WILL NOW BE REVIEWED BY EUROPEAN COMMISSION.  Full Article

Aeterna Zentaris Qtrly Loss Per Share $0.15
Wednesday, 7 Nov 2018 

Nov 6 (Reuters) - Aeterna Zentaris Inc ::AETERNA ZENTARIS REPORTS THIRD QUARTER 2018 FINANCIAL AND OPERATING RESULTS.QTRLY LOSS PER SHARE $0.15.Q3 REVENUE $663,000 VERSUS $241,000.  Full Article

Aeterna Zentaris Announces Novo Nordisk To Acquire Rights To Macrilen In U.S. And Canada
Thursday, 1 Nov 2018 

Nov 1 (Reuters) - Aeterna Zentaris Inc ::AETERNA ZENTARIS ANNOUNCES NOVO NORDISK TO ACQUIRE RIGHTS TO MACRILEN™ IN UNITED STATES AND CANADA.AETERNA ZENTARIS INC - NOVO NORDISK WILL ACQUIRE FROM STRONGBRIDGE BIOPHARMA PLC ITS RIGHTS TO MACRILEN IN UNITED STATES AND CANADA.AETERNA ZENTARIS INC - HAS LICENSED RIGHTS TO MACRILEN™ IN UNITED STATES AND CANADA TO STRONGBRIDGE BIOPHARMA.  Full Article

Aeterna Zentaris Qtrly Loss Per Share $0.03
Wednesday, 28 Mar 2018 

March 28 (Reuters) - Aeterna Zentaris Inc ::AETERNA ZENTARIS REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL AND OPERATING RESULTS.AETERNA ZENTARIS INC - AT DECEMBER 31, 2017, WE HAD $7.8 MILLION OF CASH AND CASH EQUIVALENTS.AETERNA ZENTARIS- EXPECT EXISTING CASH BALANCES WILL PROVIDE WITH ADEQUATE FUNDS TO SUPPORT CURRENT OPERATING PLAN FOR AT LEAST NEXT TWELVE MONTHS.AETERNA ZENTARIS INC QTRLY LOSS PER SHARE $0.03.  Full Article

Strongbridge Announces Acquisition Of U.S., Canadian Rights To Macrilen From Aeterna Zentaris
Wednesday, 17 Jan 2018 

Jan 17 (Reuters) - Strongbridge Biopharma Plc ::STRONGBRIDGE BIOPHARMA PLC ANNOUNCES ACQUISITION OF THE U.S. AND CANADIAN RIGHTS TO MACRILEN™ (MACIMORELIN) FROM AETERNA ZENTARIS.STRONGBRIDGE BIOPHARMA - ‍UNDER TERMS OF AGREEMENT, CO TO MAKE UPFRONT PAYMENT OF $24 MILLION TO AETERNA WITHIN 5 DAYS OF EFFECTIVE DATE OF AGREEMENT​.STRONGBRIDGE BIOPHARMA - LICENSE & ASSIGNMENT AGREEMENT ALSO PROVIDES CO WITH EXCLUSIVE LICENSE TO MANUFACTURE & COMMERCIALIZE MACRILEN IN U.S. & CANADA.STRONGBRIDGE BIOPHARMA PLC - STRONGBRIDGE EXPECTS TO COMMERCIALLY LAUNCH MACRILEN IN MID-YEAR 2018.STRONGBRIDGE BIOPHARMA PLC - ‍EXPANDS STRUCTURED FINANCING FACILITY WITH CRG TO SUPPORT ANTICIPATED COMMERCIAL LAUNCH OF MACRILEN IN MID-2018​.STRONGBRIDGE BIOPHARMA - AETERNA ZENTARIS WILL REMAIN RESPONSIBLE FOR A PEDIATRIC DEVELOPMENT PROGRAM TO SUPPORT REGULATORY SUBMISSION FOR MACRILEN APPROVAL.STRONGBRIDGE - ‍IN CONJUNCTION WITH MACRILEN DEAL, CO, CRG AMENDED EXISTING SENIOR CREDIT FACILITY TO INCREASE TOTAL POTENTIAL BORROWING TO $100 MILLION​.STRONGBRIDGE BIOPHARMA-CO SHARING OVERSIGHT AND PAYING FOR 70 PERCENT OF COST OF PEDIATRIC DEVELOPMENT PROGRAM OR ABOUT $4 MILLION OVER A 3-YEAR PERIOD​.STRONGBRIDGE - ‍UNDER AMENDED FACILITY, CO RETAINED OPTION TO BORROW ADDITIONAL $10 MILLION BASED UPON SOME CONDITIONS​.STRONGBRIDGE - ‍INTENDS TO USE UPFRONT PROCEEDS FROM SECOND BORROWING TO FUND ACQUISITON, COMMERCIALIZATION OF MACRILEN, CORPORATE PURPOSES​.  Full Article

Aeterna Zentaris Provides Update On Litigation Against David Dodd And Philip Theodore
Saturday, 23 Dec 2017 

Dec 22 (Reuters) - Aeterna Zentaris Inc ::AETERNA ZENTARIS PROVIDES UPDATE ON LITIGATION AGAINST DAVID DODD AND PHILIP THEODORE.AETERNA ZENTARIS INC - CO AND ITS CHAIR CONSIDER COUNTERCLAIM AGAINST THEM TO BE "ENTIRELY WITHOUT MERIT".AETERNA ZENTARIS - IN RECEIPT OF A STATEMENT OF DEFENCE AND COUNTERCLAIM FILED BY FORMER OFFICERS DAVID DODD AND PHILIP THEODORE.AETERNA ZENTARIS - COUNTERCLAIM ALLEGES DEFAMATORY STATEMENTS IN RESPECT OF DODD, THEODORE WERE MADE IN A CO'S PRESS RELEASE & CLAIMS DAMAGES OF $6 MILLION.  Full Article

David Dodd And Philip Theodore Respond To Claim By Aeterna Zentaris
Friday, 22 Dec 2017 

Dec 21 (Reuters) - Aeterna Zentaris Inc ::DAVID DODD AND PHILIP THEODORE RESPOND TO CLAIM BY AETERNA ZENTARIS.DAVID DODD - DODD, FORMER CEO OF AETERNA ZENTARIS & PHILIP THEODORE, CO'S FORMER GENERAL COUNSEL, HAVE RESPONDED TO CLAIM FILED AGAINST THEM BY CO.DAVID DODD SAYS DODD & PHILIP THEODORE HAVE BROUGHT A COUNTERCLAIM AGAINST CO & ITS CHAIR, CAROLYN EGBERT, IN AMOUNT OF $6.0 MILLION.DAVID DODD - DODD AND THEODORE HAVE BROUGHT COUNTERCLAIM AGAINST CO AND ITS CHAIR, CAROLYN EGBERT, IN AMOUNT OF $6.0 MILLION.  Full Article

Aeterna Zentaris Announces FDA Approval Of Macrilen For Diagnosis Of Adult Growth Hormone Deficiency
Thursday, 21 Dec 2017 

Dec 20 (Reuters) - Aeterna Zentaris Inc ::AETERNA ZENTARIS ANNOUNCES FDA APPROVAL OF MACRILEN™ (MACIMORELIN) FOR DIAGNOSIS OF ADULT GROWTH HORMONE DEFICIENCY.AETERNA ZENTARIS - INTENDS TO MAKE MACRILEN AVAILABLE COMMERCIALLY IN UNITED STATES DURING Q1 OF 2018.  Full Article

Aeterna Zentaris Announces Departure Of Interim Chief Financial Officer
Friday, 8 Dec 2017 

Dec 8 (Reuters) - Aeterna Zentaris Inc ::AETERNA ZENTARIS ANNOUNCES DEPARTURE OF INTERIM CHIEF FINANCIAL OFFICER.AETERNA ZENTARIS INC - DEPARTURE OF COMPANY'S INTERIM CHIEF FINANCIAL OFFICER, JEFFREY WHITNELL, EFFECTIVE DECEMBER 7, 2017.AETERNA ZENTARIS INC - COMMENCED A SEARCH FOR WHITNELL'S REPLACEMENT AS PRINCIPAL FINANCIAL OFFICER.  Full Article